Miller Howard Investments’s GSK GSK Stock Holding History

Miller Howard Investments’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$62M	Sell	1,182,068 -447,283	-27%	-$23.7M	1.64%	23
2026 Q1	$89.9M	Sell	1,629,351 -12,763	-0.8%	-$692K	2.46%	5
2025 Q4	$80.5M	Sell	1,642,114 -19,496	-1%	-$909K	2.43%	8
2025 Q3	$71.7M	Buy	1,661,610 +1,796	+0.1%	+$70.2K	2.19%	9
2025 Q2	$63.7M	Buy	1,659,814 +13,023	+0.8%	+$498K	2.02%	15
2025 Q1	$63.8M	Buy	1,646,791 +955,891	+138%	+$35M	2.03%	14
2024 Q4	$23.4M	Buy	+690,900	New	+$24.9M	0.77%	51
2019 Q1	–	Sell	-8,921	Closed	-$426K	–	153
2018 Q4	$426K	Sell	8,921 -2,629	-23%	-$129K	0.01%	165
2018 Q3	$580K	Sell	11,550 -2,860	-20%	-$145K	0.01%	159
2018 Q2	$726K	Sell	14,410 -23,890	-62%	-$1.2M	0.02%	154
2018 Q1	$1.87M	Buy	38,300 +1,174	+3%	+$54.7K	0.04%	133
2017 Q4	$1.65M	Sell	37,126 -1,219,923	-97%	-$56.4M	0.04%	151
2017 Q3	$63.8M	Sell	1,257,049 -43,746	-3%	-$2.22M	1.32%	36
2017 Q2	$70.1M	Sell	1,300,795 -417,137	-24%	-$22.2M	1.4%	26
2017 Q1	$90.5M	Buy	1,717,932 +79,228	+5%	+$4.02M	1.75%	14
2016 Q4	$78.9M	Sell	1,638,704 -196,147	-11%	-$9.69M	1.51%	21
2016 Q3	$98.9M	Sell	1,834,851 -47,163	-3%	-$2.59M	1.82%	18
2016 Q2	$102M	Sell	1,882,014 -76,621	-4%	-$4.04M	1.83%	17
2016 Q1	$99.3M	Buy	1,958,635 +491,201	+33%	+$24.5M	1.84%	17
2015 Q4	$74M	Sell	1,467,434 -156,068	-10%	-$7.95M	1.33%	26
2015 Q3	$78M	Sell	1,623,502 -64,191	-4%	-$3.34M	1.29%	27
2015 Q2	$87.9M	Buy	1,687,693 +265,255	+19%	+$14.9M	1.18%	29
2015 Q1	$82.1M	Buy	1,422,438 +71,315	+5%	+$4.09M	1.24%	25
2014 Q4	$72.2M	Buy	1,351,123 +77,477	+6%	+$4.33M	1.11%	31
2014 Q3	$73.2M	Buy	1,273,646 +21,352	+2%	+$1.31M	1.13%	26
2014 Q2	$83.7M	Buy	1,252,294 +24,492	+2%	+$1.66M	1.32%	23
2014 Q1	$82M	Buy	1,227,802 +13,874	+1%	+$938K	1.5%	21
2013 Q4	$81M	Sell	1,213,928 -3,412	-0.3%	-$221K	1.62%	21
2013 Q3	$76.3M	Buy	1,217,340 +21,317	+2%	+$1.37M	1.64%	20
2013 Q2	$74.7M	Buy	+1,196,023	New	+$75.9M	1.72%	20

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Miller Howard Investments's GSK Position: Q2 2026 in Review

Miller Howard Investments reduced its GSK (GSK) stake by 27% in Q2 2026, selling an estimated $23.7M and leaving 1,182,068 shares worth $62M. The position accounts for 1.64% of the portfolio, ranked #23.

Miller Howard Investments first reported a position in GSK in Q2 2013 and has held it in 30 quarters since. The position peaked at $102M in Q2 2016. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Miller Howard Investments held 1,182,068 shares of GSK worth $62M as of Q2 2026.
Miller Howard Investments sold 447,283 GSK shares in Q2 2026, an estimated $23.7M.
GSK made up 1.64% of Miller Howard Investments's portfolio in Q2 2026, its #23 holding.
Miller Howard Investments first reported a position in GSK in Q2 2013 and has held it in 30 quarters since.
Miller Howard Investments's GSK position peaked at $102M in Q2 2016.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Miller Howard Investments's 13F filing for Q2 2026, filed 31 Jul 2026.